NCT02651948

Brief Summary

Primary purpose: Complications and rehospitalizations after transperineal prostate biopsy MRI-guided are reduced than transrectal prostate biopsies. Secondary purposes:

  • Patients tolerance after transperineal prostate biopsy MRI-guided is better than after transrectal prostate biopsies.
  • Core of transperineal prostate biopsies are better than core of transrectal prostate biopsies
  • Study of correlation between radiologic images and anatomopathologic result
  • Description of needle track during the procedure
  • Description of real time template saturation prostate biopsy
  • Comparison of transperineal prostate biopsy relevance according to EBM
  • Comparison of 1.5T MRI and 3T MRI for prostate cancer detection

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for phase_4 prostate-cancer

Timeline
Completed

Started May 2015

Longer than P75 for phase_4 prostate-cancer

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2015

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

December 23, 2015

Completed
19 days until next milestone

First Posted

Study publicly available on registry

January 11, 2016

Completed
7.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2023

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2024

Completed
Last Updated

December 19, 2025

Status Verified

December 1, 2025

Enrollment Period

8.3 years

First QC Date

December 23, 2015

Last Update Submit

December 12, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Collection of complications and rehospitalizations by using questionnaire

    12 months

Study Arms (2)

Transperineal prostate biopsy (TPB)

EXPERIMENTAL

Transperineal prostate biopsy MRI-guided

Procedure: Transrectal prostate biopsy (TRB):

Transrectal prostate biopsy (TRB)

ACTIVE COMPARATOR

Transrectal prostate biopsy echo-guided

Procedure: Transperineal, MRI-guided, prostate biopsy

Interventions

Transrectal prostate biopsy (TRB)
Transperineal prostate biopsy (TPB)

Eligibility Criteria

Age40 Years - 80 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men
  • to 80 years' old
  • Affiliation to French social health system
  • Signed consent
  • Prostate cancer suspicion based on prostate specific antigen (PSA) or digital rectal exam WITH abnormal MRI (Prostate Imaging Reporting and Data System score 3) AND negative transrectal prostate biopsies
  • Patient treated by active surveillance for a low risk prostate cancer (T1c or T2a, Gleason = 6, PSA \< 10)

You may not qualify if:

  • Gleason \> 6 prostate cancer
  • Metastatic prostate cancer
  • Contraindication to MRI
  • Contraindication to general anesthesia
  • Non-reversible hemostasis trouble
  • Inability to give consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Service d'urologie

Strasbourg, 67000, France

Location

Related Publications (1)

  • Tricard T, Cazzato RL, Poussot B, Gaillard V, Labani A, De Mathelin M, Barhoumi C, Sauleau E, Gangi A, Roy C, Lang H. Transperineal MR Imaging-Guided Prostate Biopsy: A Prospective Randomized Controlled Study on Safety and Effectiveness Compared with Transrectal Biopsy. J Vasc Interv Radiol. 2025 Aug;36(8):1278-1284. doi: 10.1016/j.jvir.2025.05.015. Epub 2025 May 17.

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 23, 2015

First Posted

January 11, 2016

Study Start

May 1, 2015

Primary Completion

August 1, 2023

Study Completion

February 1, 2024

Last Updated

December 19, 2025

Record last verified: 2025-12

Locations